Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.

Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer

Novel non-chain terminating nucleoside analog anti-HIV inhibitor

Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder

Novel inhibitor of amyloid-

Novel Potent and Selective EP4 Agonist

Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor

Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

Selective S1P3 agonist

CDK9 inhibitor, inhibiting transcription of GAPDH

0

Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr)

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel

Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs)

Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor

Potent D3 receptor antagonist with high 5-HT1A receptor affinity

Novel specific inhibitor of MYC

Novel TRPV1 antagonist

Novel ROS1 kinase inhibitor

Novel ROS1 kinase inhibitor

Novel potent and selective inhibitor of kir1.1 channels